ReviewDeutsches Arzteblatt international2010
Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions.
Review in Deutsches Arzteblatt international, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- The Differential Effects of Alzheimer's Disease and Lewy Body Pathology on Cognitive Performance: a Meta-analysis.Neuropsychology review · 2017Pooled it
- Cholinesterase inhibitors for rarer dementias associated with neurological conditions.The Cochrane database of systematic reviews · 2015Pooled it
- Enhanced quantitation of pathological α-synuclein in patient biospecimens by RT-QuIC seed amplification assays.PLoS pathogens · 2024Article
- An induced pluripotent stem cell-derived NMJ platform for study of the NGLY1-Congenital Disorder of Deglycosylation.Advanced therapeutics · 2022Article
- Survival among the older adults with clinical signs of Lewy body dementia in 40 Swedish nursing homes: a 6-year follow-up study.BMJ open · 2019Observational
- Lewy Body Disease: Clinical and Pathological "Overlap Syndrome" Between Synucleinopathies (Parkinson Disease) and Tauopathies (Alzheimer Disease).Current neurology and neuroscience reports · 2018Review
- Psychotropic and anti-dementia treatment in elderly persons with clinical signs of dementia with Lewy bodies: a cross-sectional study in 40 nursing homes in Sweden.BMC geriatrics · 2018Article
- Improving Safety in Health Care for Patients With Neurocognitive Disorders and High Risk of Falls.Focus (American Psychiatric Publishing) · 2017Article
- Orthostatic Circulatory Disorders: From Nosology to Nuts and Bolts.American journal of hypertension · 2016Review
- Neurophysiological biomarkers for Lewy body dementias.Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2016Review
- Genetics and underlying pathology of dementia.Neuropsychology review · 2015Review
- [Parkinson's disease and psychoses].Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater · 2015Review
- Changes of brain gray matter structure in Parkinson's disease patients with dementia.Neural regeneration research · 2013Article
- Gaucher disease and the synucleinopathies: refining the relationship.Orphanet journal of rare diseases · 2012Review
- Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions: Evidence is not satisfactory.Deutsches Arzteblatt international · 2011Article
- Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions: Hydrocephalus should not be forgotten.Deutsches Arzteblatt international · 2011Article
- The investigation and differential diagnosis of dementias.Deutsches Arzteblatt international · 2010Article
- NMR Metabolomics Analysis of Parkinson's Disease.Current MetabolomicsArticle
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
6 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are the two most common types of dementing neurodegenerative disease after Alzheimer's disease (AD). Both of these conditions are often diagnosed late or not at all.
methodsSelective literature review.
resultsThe severe cholinergic and dopaminergic deficits that are present in both DLB and PDD produce not only motor manifestations, but also cognitive deficits, mainly in the executive and visual-constructive areas, as well as psychotic manifestations such as visual hallucinations, delusions, and agitation. The intensity of these manifestations can fluctuate markedly over the course of the day, particularly in DLB. Useful tests for differential diagnosis include magnetic resonance imaging and electroencephalography; in case of clinical uncertainty, nuclear medical procedures and cerebrospinal fluid analysis can be helpful as well. Neuropathological studies have revealed progressive alpha-synuclein aggregation in affected areas of the brain. In DLB, beta-amyloid abnormalities are often seen as well.
conclusionDLB should be included in the differential diagnosis of early dementia. If motor manifestations arise within one year (DLB), dopaminergic treatment should be initiated. On the other hand, patients with Parkinson's disease should undergo early screening for signs of dementia so that further diagnostic and therapeutic steps can be taken in timely fashion, as indicated. Cholinesterase inhibitors are useful for the treatment of cognitive deficits and experiential/behavioral disturbances in both DLB (off-label indication) and PDD (approved indication).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.